Observational Study in Patients With Nail Psoriasis Treated With Enstilar® to Assess the Severity Change and the Quality of Life (ENUPS)

Angeles Florez

Status: Completed

Conditions: Nail Psoriasis

Treatments: Drug: Calcipotriene and betamethasone dipropionate aerosol foam

Study type: Observational

Funder types: Other

Identifiers

NCT04380597

ENUPS

Details and patient eligibility

About

Observational, prospective and multicentre study to evaluate the effectiveness of calcipotriene and betamethasone dipropionate aerosol foam (Cal / BD), prescribed according to clinical practice and following the Product Data Sheet instructions, in the topical treatment of nail psoriasis according to the change in the score of the Nail Psoriasis Severity Index (NAPSI) at 12 weeks of treatment with respect to the initial score.

Enrollment: 10 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with nail psoriasis who start, according to clinical practice, topical treatment with calcipotriene and betamethasone dipropionate aerosol foam
• Patients who authorize their participation in the study by signing written informed consent.

Exclusion criteria

• Patients receiving treatment with systemic drugs or their prescription is scheduled for the next 3 months. However, may be included patients who receive the same systemic treatment regimen from at least 6 months before their inclusion in the study and up to 14 weeks later.
• Patients with any situation or state that in the opinion of the investigator discourages their participation in the study.

Trial design

10 participants in 1 patient group

Patients with nail psoriasis

Description:

Patients with nail psoriasis who are prescribed, according to clinical practice, a topical treatment with calcipotriene and betamethasone dipropionate aerosol foam.

Treatment:

Drug: Calcipotriene and betamethasone dipropionate aerosol foam